News >

TAS-102 Continues to Demonstrate Efficacy, Safety in CRC and Gastric Cancers

Kristi Rosa
Published: Monday, Jun 24, 2019

Howard S. Hochster, MD

Howard S. Hochster, MD

Results from a pooled safety analysis of phase III trials of TAS-102 (trifluridine/tipiracil; Lonsurf) show that the agent can be used in patients with colorectal cancer (CRC) and gastric/gastroesophageal junction (GEJ) cancer alike with similar rates of efficacy and toxicity.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x